Regulus Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch RGLS and buy or sell other stocks, ETFs, and their options commission-free!

About RGLS

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. 

CEO
Joseph P. Hagan
CEOJoseph P. Hagan
Employees
26
Employees26
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2007
Founded2007
Employees
26
Employees26

RGLS Key Statistics

Market cap
1.19B
Market cap1.19B
Price-Earnings ratio
—
Price-Earnings ratio—
Dividend yield
—
Dividend yield—
Average volume
1.25M
Average volume1.25M
High today
—
High today—
Low today
—
Low today—
Open price
—
Open price—
Volume
0.00
Volume0.00
52 Week high
$0.8724
52 Week high$0.8724
52 Week low
$0.1576
52 Week low$0.1576

People also own

Based on the portfolios of people who own RGLS. This list is generated using Robinhood data, and it’s not a recommendation.
SNDL
NIO
Lucid Group
Tilray Brands
Tonix Pharmaceuticals
Ocugen, Inc
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.